See more : Quebecor Inc. (QBR-A.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Cortexyme, Inc. (CRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cortexyme, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Levere Holdings Corp. (LVRAU) Income Statement Analysis – Financial Results
- LBX Pharmacy Chain Joint Stock Company (603883.SS) Income Statement Analysis – Financial Results
- PT Grand Kartech Tbk (KRAH.JK) Income Statement Analysis – Financial Results
- The Western Union Company (W3U.DE) Income Statement Analysis – Financial Results
- Orange S.A. (ORAN) Income Statement Analysis – Financial Results
Cortexyme, Inc. (CRTX)
About Cortexyme, Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -90.32M | -78.89M | -39.17M | -11.47M | -10.55M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.95M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 373.00K | 2.04M | 2.19M | 600.00K | -222.00K |
| Net Income | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| EPS Diluted | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today appeared first on...
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases.
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks
Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for...
After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)
The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock...
5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI
Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI appeared first on InvestorPlace.
Cortexyme Stock Sinks After FDA Puts Application on Hold
Cortexyme Inc (NASDAQ:CRTX) is plummeting today, last seen down 31.1% at $6.25, after the U.S. Food and Drug Administration (FDA) placed the company's application to start a study of its lead drug for Alzheimer's disease on hold.
Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND
The Company plans to provide additional updates pending continued engagement with FDA.
Why Cortexyme Stock Imploded in 2021
A key clinical setback sent investors to the exits last year.
3 Most-Shorted Stocks at 52-Week Lows to Buy
In a market made up of stocks, these three most-shorted stocks look poised to deliver a much happier 2022 to bullish investors. The post 3 Most-Shorted Stocks at 52-Week Lows to Buy appeared first on InvestorPlace.
Source: https://incomestatements.info
Category: Stock Reports